Phagenesis appoints chairman and ceo
Will lead the development of treatments for stroke victims
Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.
Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.
You may also like
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Research & Development
EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health
The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications